Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours
Authors:
- 1 August 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 38 (12) , 1615-1621
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- D-21266, a new heterocyclic alkylphospholipid with antitumour activityEuropean Journal of Cancer, 1997
- Three paths to stress reliefNature, 1996
- Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancerEuropean Journal of Cancer, 1993
- A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursJournal of Cancer Research and Clinical Oncology, 1992
- Hexadecylphosphocholine in the Topical Treatment of Skin Metastases in Breast Cancer Patients1992
- Antitumoral Activity of Alkylphosphocholines and Analogues in Human Leukemia Cell Lines1992
- Effects of Hexadecylphosphocholine on Cellular Function1992
- Hexadecylphosphocholine, a New Ether Lipid Analogue Studies on the Antineoplastic Activity in Vitro and in VivoActa Oncologica, 1989
- Effect of lipid derivatives on invasion in vitro and on surface glycoproteins of three rodent cell typesLipids, 1987
- Accumulation of an alkyl lysophospholipid in tumor cell membranes affects membrane fluidity and tumor cell invasionLipids, 1987